Roche Analyst Event at ISTH 2017



Daniel O’Day, CEO Roche Pharmaceuticals

HAVEN1: Ph3 data of emicizumab (ACE910) prophylaxis in adults with hemophilia A with inhibitors
Prof. Dr. med. Johannes Oldenburg, University Clinic Bonn, Institute of Experimental Hematology and Transfusion Medicine

HAVEN2: Ph3 interim data of emicizumab (ACE910) prophylaxis in pediatrics with hemophilia A with inhibitors; aspects of disease management and emicizumab global development program
Gallia Levy, M.D., Ph.D., Global Development Team Leader emicizumab

Webcast Replay